FIELD: medicine.
SUBSTANCE: invention refers to new pyridine derivatives or to their pharmaceutically acceptable salts of general formula 1: 
wherein R1, R2, R3, R4, R5, R6 and R7 are independently chosen from the group including hydrogen atom, halogen, amino, C1-C6lower alkyl, C2-C6lower alkenyl, C1-C6lower alkoxy, C1-C10alkylamino, C4-C9cycloalkylamino, C4-C9heterocycloalkylamino, C1-C10aralkylamino, arylamino, acylamino, saturated heterocyclyl, acyloxy, aryl, heteroaryl, C1-C10aralkyl, aryloxy; X represents oxygen or sulphur atom; Y represents oxygen atom or N-R8, wherein R8 is chosen from the group including hydrogen atom; aforesaid aryl group is chosen from phenyl, naphthyl and condensed phenyl group; aforesaid heteroaryl and saturated heterocyclic groups represent pentagonal or hexagonal heterocyclic ring containing 1 to 2 heteroatoms chosen from oxygen, nitrogen and sulphur atom; or condensed heterocyclic ring; and aforesaid aryl and heteroaryl groups are those that 1 to 4 assistants chosen from group including halogen, C1-C6lower alkyl, C1-C6lower alkoxy are substituted. And specified compounds or their pharmaceutically acceptable salt of formula 1 are not compounds as follows 6-methyl-3,4-dihydro-pyrano[3,4-c]pyridin-1-one, 5-vinyl-3,4-dihydro-pyrano[3,4-c]pyridin-1-one, 6-methyl-8-furan-2-yl-3,4- dihydropyrano[3,4-c]pyridin-1-one, 3-tert-butyl-5,6,7,8-tetrahydro-[2,7]naphthyridine-8-one and dimethyl ether (3S)-6,8-dimethyl-1-oxo-1,2,3,4-tetrahydro-[2,7]naphthyridine-3,5-dicarboxylic acids.
EFFECT: compounds possess inhibitory action with respect to formation of cytokines involved in inflammatory reactions, can be used as a therapeutic agent for treatment of inflammatory diseases, immune diseases, chronic inflammations; it provides antiinflammatory and analgesic action.
21 cl, 7 tbl, 144 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDOLE AND INDAZOLE DERIVATIVES SHOWING PRESERVING ACTION ON CELLS, TISSUES AND ORGANS | 2009 |
|
RU2460525C2 |
| COMPOUNDS HAVING INHIBITORY ACTIVITY RELATIVELY TO PDE9A AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2788147C2 |
| NOVEL DERIVATIVE OF PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYLSULPHONAMIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITION, WHICH HAS INHIBITION ACTIVITY WITH RESPECT TO RAF-KINASE, CONTAINING CLAIMED COMPOUND AS ACTIVE INGREDIENT | 2011 |
|
RU2550038C2 |
| ISOQUINOLINONE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-ribose)POLYMERASE-1, CONTAINING THEM AS ACTIVE INGREDIENT | 2020 |
|
RU2815480C1 |
| COMPOUNDS HAVING INHIBITORY ACTIVITY RELATIVELY TO PDE9A AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2788148C2 |
| 1,3-DIOXOINDENE DERIVATIVES, THEREOF PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL ANTIVIRAL COMPOSITION, CONTAINING IT AS ACTIVE INGREDIENT | 2012 |
|
RU2566761C2 |
| TETRAHYDROPYRIDINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | 2017 |
|
RU2722594C1 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
| 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | 2012 |
|
RU2612958C2 |
| ORALLY BIOAVAILABLE PRODRUGS OF (+)-3-HYDROXYMORPHINAN FOR PREVENTING OR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2430089C2 |
